What are the risks, side effects, and signs of ivermectin overdose in humans?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin at approved human doses is generally well tolerated for specified parasitic infections, but overdoses—especially from veterinary formulations—can cause gastrointestinal symptoms (nausea, vomiting, diarrhea), cardiovascular effects (hypotension), and serious neurologic problems including confusion, ataxia, seizures, coma and death, according to FDA and CDC warnings [1] [2]. Health agencies and medical reviewers urge anyone who may have taken too much to seek emergency care or contact poison control; several case reports and reviews describe encephalopathy, liver injury, and increased poison-control calls during the COVID era when non‑prescribed use rose [3] [4] [5].
1. What ivermectin is, how people began misusing it
Ivermectin is an antiparasitic drug approved for specific human uses (intestinal strongyloidiasis, onchocerciasis) and widely used in veterinary medicine; during the COVID‑19 pandemic it was promoted online and in some politics-driven campaigns, driving people to self‑treat with human and animal products—sometimes highly concentrated veterinary formulations—creating safety concerns and a marked rise in prescriptions and poison‑center calls [1] [2] [6].
2. Common and expected side effects at therapeutic doses
When taken as prescribed for humans, side effects are typically uncommon and usually mild: fever, pruritus or skin rash, headache, dizziness or drowsiness, and gastrointestinal upset have been reported in product information and drug references [7] [8] [9]. The European Medicines Agency and manufacturer safety monitoring continue to evaluate suspected side effects and include guidance for healthcare professionals [10].
3. Symptoms and signs associated with overdose or toxicity
Federal agencies and clinical reviews list a consistent toxidrome: gastrointestinal upset (nausea, vomiting, diarrhea), hypotension, allergic reactions (itching, hives), and central‑nervous‑system effects ranging from dizziness, ataxia and confusion to hallucinations, seizures, stupor, coma and death in severe cases [1] [2] [4]. Multiple clinical summaries add liver injury and encephalopathy to reported severe adverse events in real‑world cases [5] [11].
4. Why veterinary products are particularly risky
Veterinary ivermectin formulations for horses or cattle are far more concentrated and not tested for human use; consuming them has led to severe overdoses and hospitalizations because dosing intended for large animals can vastly exceed safe human levels [2] [12]. The FDA explicitly warned against using animal products on people, and public health messaging emphasized “You are not a horse” to discourage this practice [2] [12].
5. Vulnerable groups and special clinical concerns
People with certain genetic or physiologic vulnerabilities may be at higher risk: defects in the ABCB1/P‑glycoprotein transporter can permit ivermectin to enter the central nervous system and cause neurotoxicity even at lower doses (case literature summarized in reviews) [4] [11]. Heavily infected patients with specific parasites (e.g., high Loa loa burden) have also experienced severe reactions after treatment, and limited data exist for children under 15 kg, pregnancy, and breastfeeding—regulators caution use in those groups [7].
6. Management: what to do if overdose is suspected
Authoritative consumer and clinical sources instruct people to seek emergency care for severe symptoms and to call poison control (1‑800‑222‑1222 in the U.S.) or the FDA adverse‑event line; there is no specific antidote for ivermectin poisoning and management is supportive, guided by symptom severity [3] [4] [1]. Published case reports and reviews note that supportive care and monitoring of neurologic and hemodynamic status are the mainstays of treatment [4] [11].
7. Context, controversies, and public‑health implications
While some researchers are investigating repurposed roles for ivermectin (including early cancer or adjunctive trials), major public‑health bodies — WHO, EMA, FDA and national specialty societies — do not endorse ivermectin for COVID‑19 and warn against self‑medication; mis- or disinformation and state-level moves to deregulate access have intensified concerns about unsupervised use and overdoses [13] [6] [12]. Reporting shows spikes in prescriptions and poison‑center contacts aligned with media and political attention, illustrating how nonclinical promotion can amplify risk [2] [14].
8. Limitations in available reporting and what is not in these sources
Available sources document symptoms, warnings, case reports, and regulatory positions, but do not provide a single, universally accepted human “toxic dose” or clear therapeutic windows for off‑label high‑dose regimens; some non‑peer sites quote toxic dose numbers but those claims are inconsistent and not corroborated across regulatory and clinical reviews in this set [15] [1] [4]. Large‑scale epidemiologic quantification of overdose incidence beyond poison‑control trends is not detailed in these materials [2] [3].
If you or someone may have taken excess ivermectin, contact emergency services immediately for severe symptoms, or call your local poison control center as advised by medical sources [3] [1].